Abstract
Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 19-28 |
| Number of pages | 10 |
| Journal | Lancet Neurology |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2004 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Dementia with Lewy bodies. / McKeith, Ian; Mintzer, Jacobo; Aarsland, Dag; Burn, David; Chiu, Helen; Cohen-Mansfield, Jiska; Dickson, Dennis W; Dubois, Bruno; Duda, John E.; Feldman, Howard; Gauthier, Serge; Halliday, Glenda; Lawlor, Brian; Lippa, Carol; Lopez, Oscar L.; Carlos MacHado, João; O'Brien, John; Playfer, Jeremy; Reid, Wayne.
In: Lancet Neurology, Vol. 3, No. 1, 01.01.2004, p. 19-28.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dementia with Lewy bodies
AU - McKeith, Ian
AU - Mintzer, Jacobo
AU - Aarsland, Dag
AU - Burn, David
AU - Chiu, Helen
AU - Cohen-Mansfield, Jiska
AU - Dickson, Dennis W
AU - Dubois, Bruno
AU - Duda, John E.
AU - Feldman, Howard
AU - Gauthier, Serge
AU - Halliday, Glenda
AU - Lawlor, Brian
AU - Lippa, Carol
AU - Lopez, Oscar L.
AU - Carlos MacHado, João
AU - O'Brien, John
AU - Playfer, Jeremy
AU - Reid, Wayne
PY - 2004/1/1
Y1 - 2004/1/1
N2 - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.
AB - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.
UR - http://www.scopus.com/inward/record.url?scp=9144224226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9144224226&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(03)00619-7
DO - 10.1016/S1474-4422(03)00619-7
M3 - Article
C2 - 14693108
AN - SCOPUS:9144224226
VL - 3
SP - 19
EP - 28
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 1
ER -